

NOVO NORDISK A S
Form 6-K
August 09, 2012

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

AUGUST 9, 2012

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

**Novo Allé
DK- 2880, Bagsvaerd
Denmark**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____

Company Announcement

Financial report for the period 1 January 2012 to 30 June 2012

9 August 2012

Novo Nordisk increased operating profit by 31% in the first half of 2012 Sales grew 17% driven by Victoza[®], NovoRapid[®] and Levemir[®]

Sales grew 17% to 37.2 billion in Danish kroner and by 12% in local currencies.

- o Sales of modern insulins increased by 20% (15% in local currencies).[®]
- o Sales of Victoza increased by 82% (73% in local currencies).
- o Sales in North America increased by 29% (19% in local currencies).
- o Sales in International Operations increased by 19% (17% in local currencies)

Reported gross margin improved by 1.3 percentage points to 81.7%.

Reported operating profit increased by 31% to DKK 14,038 million. Measured in local currencies, operating profit increased by 21%.

Net profit increased by 22% to DKK 10,010 million. Earnings per share (diluted) increased by 26% to DKK 17.99.

The regulatory reviews of the new ultra-long-acting insulins, with the intended brand names Tresiba[®] and Ryzodeg[®], progress in the major markets. In the US, the review has been extended with the tentative scheduling of an FDA advisory committee meeting 8 November.

The first phase 3a trial for IDegLira, a fixed ratio combination of insulin degludec and liraglutide, demonstrates superior glucose control in the IDegLira-treated patients while reconfirming the competitive profiles of Tresiba[®] and Victoza[®].

In the recently completed pivotal phase 3 trial for vatreptacog alfa, a fast-acting recombinant coagulation factor VIIa analogue, one patient developed antibodies with a potentially neutralising effect. The impact of this finding on the project is currently being evaluated.

For 2012, sales growth measured in local currencies is now expected to be 9-12% (previously 8-11%), and operating profit growth measured in local currencies is now expected to be around 15% (previously at least 10%).

Lars Rebien Sørensen, president and CEO: We are very satisfied with the financial performance in the first half of 2012, driven by a continued strong performance of our modern insulins and Victoza[®]. We are also encouraged by the IDegLira data which show the benefits of Tresiba[®] in combination with Victoza[®].

Edgar Filing: NOVO NORDISK A S - Form 6-K

| | | | | |
|-------------------------|--------------------------|---------------|-----------------|-------------|
| Novo Nordisk A/S | Novo Allé | Telephone: | Internet: | CVR number: |
| Investor Relations | 2880 Bagsværd Denmark | +45 4444 8888 | novonordisk.com | 24256790 |
| | | Telefax: | | |
| | | +45 4444 6626 | | |

Consolidated financial statements for the first six months of 2012

The present unaudited consolidated financial statements for the first six months of 2012 have been prepared in accordance with IAS 34 Interim Financial Reporting and on the basis of the same accounting policies as applied in the Annual Report 2011 of Novo Nordisk. Furthermore, the financial report, including the consolidated financial statements for the first six months of 2012 and Management's review, has been prepared in accordance with additional Danish disclosure requirements for interim reports of listed companies. Novo Nordisk has adopted all new, amended or revised accounting standards and interpretations (IFRSs) endorsed by the EU effective for the accounting period beginning on 1 January 2012. These IFRSs have not had a significant impact on the consolidated financial statements for the first six months of 2012.

Amounts in DKK million, except average number of shares outstanding, earnings per share and full-time employees.

| | H1 2012 | H1 2011 | % change H1 2011 to H1 2012 |
|--|---------------|---------------|---|
| <u>Profit and loss</u> | | | |
| Sales | 37,219 | 31,694 | 17% |
| Gross profit | 30,392 | 25,478 | 19% |
| <i>Gross margin</i> | <i>81.7%</i> | <i>80.4%</i> | |
| Sales and distribution costs | 10,053 | 8,893 | 13% |
| <i>Percentage of sales</i> | <i>27.0%</i> | <i>28.1%</i> | |
| Research and development costs | 5,070 | 4,613 | 10% |
| <i>Percentage of sales</i> | <i>13.6%</i> | <i>14.6%</i> | |
| Administrative expenses | 1,555 | 1,534 | 1% |
| <i>Percentage of sales</i> | <i>4.2%</i> | <i>4.8%</i> | |
| Licence fees and other operating income | 324 | 245 | 32% |
| Operating profit | 14,038 | 10,683 | 31% |
| <i>Operating margin</i> | <i>37.7%</i> | <i>33.7%</i> | |
| Net financials | (1,038) | (25) | N/A |
| Profit before income taxes | 13,000 | 10,658 | 22% |
| Net profit | 10,010 | 8,207 | 22% |
| <i>Net profit margin</i> | <i>26.9%</i> | <i>25.9%</i> | |
| <u>Other key numbers</u> | | | |
| Depreciation, amortisation and impairment losses | 1,294 | 1,430 | (10%) |
| Capital expenditure | 1,371 | 1,176 | 17% |

Edgar Filing: NOVO NORDISK A S - Form 6-K

| | | | |
|--|--------------|--------------|------------|
| Net cash generated from operating activities | 12,738 | 9,639 | 32% |
| Free cash flow | 11,311 | 8,295 | 36% |
| Total assets | 60,978 | 61,528 | (1%) |
| Equity | 31,334 | 36,966 | (15%) |
| Equity ratio | 51.4% | 60.1% | |
| Average number of shares outstanding (million) - diluted | 556.4 | 575.3 | (3%) |
| Diluted earnings per share / ADR (in DKK) | 17.99 | 14.27 | 26% |
| Full-time employees at the end of the period | 32,819 | 31,549 | 4% |

Company Announcement No 50 / 2012
 Financial report for the period 1 January 2012 to 30 June 2012

Page 2 of 24

Novo Nordisk A/S Novo Allé
 2880 Bagsværd
 Investor Relations Denmark

Telephone: +45 4444 8888
 Internet: novonordisk.com
 Telefax: +45 4444 6626

CVR number:
 24256790

Sales development

Sales increased by 17% in Danish kroner and by 12% measured in local currencies compared to the first six months of 2011. North America was the main contributor to growth with 64% share of growth measured in local currencies, followed by International Operations and Region China, contributing 21% and 9%, respectively. The majority of growth originated from the modern insulins and Victoza®. Sales growth was negatively impacted by close to 1.5 percentage points due to healthcare and pricing reforms in several European markets, the US, International Operations and China.

| | Sales H1 2012 DKK million | Growth as reported | Growth in local currencies | Share of growth in local currencies |
|---------------------------------------|--|-----------------------------------|---|--|
| The diabetes care segment | | | | |
| Modern insulins | 16,480 | 20% | 15% | 54% |
| NovoRapid® | 7,346 | 22% | 15% | 25% |
| NovoMix® | 4,488 | 12% | 7% | 7% |
| Levemir® | 4,646 | 28% | 22% | 22% |
| Human insulins | 5,499 | 4% | (1%) | (2%) |
| Protein-related products | 1,246 | 7% | 2% | 1% |
| Victoza® | 4,283 | 82% | 73% | 46% |
| Oral antidiabetic products | 1,369 | 0% | (6%) | (2%) |
| Diabetes care total | 28,877 | 21% | 15% | 97% |
| The biopharmaceuticals segment | | | | |
| NovoSeven® | 4,360 | 5% | 0% | 0% |
| Norditropin® | 2,786 | 15% | 9% | 6% |
| Other products | 1,196 | (3%) | (8%) | (3%) |
| Biopharmaceuticals total | 8,342 | 6% | 1% | 3% |
| Total sales | 37,219 | 17% | 12% | 100% |

In the following sections, unless otherwise noted, market data are based on moving annual total (MAT) from May 2012 and May 2011 provided by the independent data provider IMS Health.

Diabetes care sales development

Sales of diabetes care products increased by 21% measured in Danish kroner to DKK 28,877 million and by 15% in local currencies. Novo Nordisk is the world leader in diabetes care and now holds a global value market share of 25% compared to 24% at the same point in time last year.

Modern insulins, human insulins and protein-related products

Sales of modern insulins, human insulins and protein-related products increased by 15% in Danish kroner to DKK 23,225 million and by 10% measured in local currencies, with North America and International Operations having the highest growth rates. Novo Nordisk is the global leader with 50% of the total insulin market and 46% of the modern insulin market.

Sales of modern insulins increased by 20% in Danish kroner to DKK 16,480 million and by 15% in local currencies. North America accounted for more than half of the growth, followed by Region China and International Operations. Sales of modern insulins now constitute 75% of Novo Nordisk's sales of insulin.

Edgar Filing: NOVO NORDISK A S - Form 6-K

Company Announcement No 50 / 2012
Financial report for the period 1 January 2012 to 30 June 2012

Page 3 of 24

Novo Nordisk A/S Novo Allé
2880 Bagsværd
Investor Relations Denmark

Telephone:
+45 4444 8888
Telefax:
+45 4444 6626

Internet:
novonordisk.com

CVR number:
24256790

| Insulin market shares (volume, MAT) | Novo Nordisk's share of total insulin market | | Novo Nordisk's share of modern insulin market | |
|--|--|------------|--|------------|
| | May 2012 | May 2011 | May 2012 | May 2011 |
| Global | 50% | 50% | 46% | 46% |
| USA | 41% | 41% | 37% | 37% |
| Europe | 51% | 52% | 50% | 50% |
| International Operations* | 59% | 59% | 56% | 56% |
| Japan | 57% | 61% | 52% | 55% |
| China** | 62% | 63% | 66% | 68% |

Source: IMS Health, IMS Midas Quantum data, May 2012

*: Data for 12 selected markets representing approximately 60% of diabetes sales in the region

**: Data for mainland China, excluding Hong Kong and Taiwan

North America

Sales of modern insulins, human insulins and protein-related products in North America increased by 27% in Danish kroner and by 18% in local currencies, reflecting a continued solid market penetration of the modern insulins, NovoLog[®], Levemir[®] and NovoLog[®] Mix 70/30, partly countered by a continued decline in human insulin sales. Currently, around 48% of Novo Nordisk's modern insulin volume in the US is being sold in the prefilled device FlexPen[®] compared to around 44% in 2011.

Europe

Sales of modern insulins, human insulins and protein-related products in Europe remained unchanged both in Danish kroner and in local currencies. Sales in Europe reflect a continued progress for NovoRapid[®] and Levemir[®] partly countered by declining human insulin sales. Sales growth in Europe is negatively impacted by a continued low insulin volume growth, below 3%, gradual market share losses and by the implementation of healthcare reforms in a number of European markets. The device penetration in Europe remains high with more than 96% of Novo Nordisk's insulin volume being used in devices, primarily NovoPen[®] and FlexPen[®].

International Operations

Sales of modern insulins, human insulins and protein-related products in International Operations increased by 19% in Danish kroner and by 17% in local currencies. The growth is driven by all three modern insulins and with solid contribution from human insulin. Currently, around 58% of Novo Nordisk's insulin volume in the major private markets is being sold for use in devices.

Region China

Sales of modern insulins, human insulins and protein-related products in Region China increased by 27% in Danish kroner and by 14% in local currencies. The sales growth was driven by all three modern insulins, while sales of human insulin only grew modestly. Currently, around 97% of Novo Nordisk's insulin volume in China is being sold for use in devices, primarily Penfill[®] for use in the durable device NovoPen[®].

Japan & Korea

Sales of modern insulins, human insulins and protein-related products in Japan & Korea increased by 3% measured in Danish kroner but declined by 7% in local currencies. Sales growth is negatively impacted by a lack of volume growth in the Japanese market and a continuously challenging competitive environment. Novo Nordisk now holds 57% of the total insulin market in Japan and 52% of the modern insulin market. The device penetration in

Company Announcement No 50 / 2012
Financial report for the period 1 January 2012 to 30 June 2012

Page 4 of 24

Novo Nordisk A/S Novo Allé
2880 Bagsværd
Denmark

Telephone:
+45 4444 8888
Telefax:
+45 4444 6626

Internet:
novonordisk.com

CVR number:
24256790

Japan remains high with more than 98% of Novo Nordisk's insulin volume being used in devices, primarily the FlexPen®.

Victoza® (GLP-1 therapy for type 2 diabetes)

Victoza® sales reached DKK 4,283 million, reflecting solid sales performance in all regions. The global roll-out is continuing, with 53 countries having launched Victoza® by the end of June 2012 and more than 10 countries preparing to launch in the second half of 2012. Victoza® holds the global market share leadership with a 65% market share in the GLP-1 segment compared to 47% in 2011. The GLP-1 class share of the total diabetes care market has increased to 5.1% compared to 3.8% in 2011.

| GLP-1 market shares (value, MAT) | GLP-1 share of total diabetes care market | | Victoza® share of GLP-1 market | |
|-------------------------------------|--|-------------|-----------------------------------|------------|
| | May 2012 | May 2011 | May 2012 | May 2011 |
| Global | 5.1% | 3.8% | 65% | 47% |
| USA | 6.3% | 5.0% | 58% | 41% |
| Europe | 5.8% | 4.3% | 73% | 59% |
| International Operations* | 2.5% | 0.4% | 79% | 18% |
| Japan | 2.1% | 0.8% | 82% | 92% |
| China** | 0.4% | 0.2% | 23% | 0% |

Source: IMS Health, IMS Midas Quantum data, May 2012

*: Data for 12 selected markets representing approximately 60% of diabetes sales in the region

** : Data for mainland China, excluding Hong Kong and Taiwan

North America

Sales of Victoza® in North America increased by 81% in Danish kroner and by 69% measured in local currencies. This reflects a continued expansion of the GLP-1 class, which represents 6.3% of the total US diabetes care market compared to 5.0% in 2011. Despite the launch of a competitive product, Victoza® continues to drive the US GLP-1 market expansion and is the GLP-1 market leader with a 58% market share.

Europe

Sales in Europe increased by 60% in Danish kroner and by 59% measured in local currencies. This reflects continued roll-out across Europe and in particular sales growth in France, Italy, the UK and Spain. In Europe, the GLP-1 class share of the total diabetes care market has increased to 5.8% compared to 4.3% in 2011. Victoza® is the GLP-1 market leader with a market share of 73%.

International Operations

Sales in International Operations increased by 293% in Danish kroner and by 306% measured in local currencies. This reflects continued strong performance, driven by Brazil and certain Middle Eastern countries and a modest comparison base in 2011. The GLP-1 class is expanding in International Operations and represents 2.5% of the total diabetes care market compared to 0.4% in 2011. The significant expansion of the GLP-1 class is driven by a strong uptake in Brazil. Victoza® is the GLP-1 market leader across International Operations, with a market share of 79%.

Region China

Victoza® was launched in China during the fourth quarter of 2011. Early market feedback is positive and hospital listings are developing satisfactorily. The GLP-1 class in China is relatively modest in size, but its share of the total diabetes care market is expanding to 0.4% compared to 0.2% in 2011. Victoza® holds a GLP-1 market share of 23%.

Company Announcement No 50 / 2012

Financial report for the period 1 January 2012 to 30 June 2012

Novo Nordisk A/S Novo Allé
2880 Bagsværd
Investor Relations Denmark

Telephone: +45 4444 8888
Internet: novonordisk.com
Telefax:

Page 5 of 24

CVR number:
24256790

Japan & Korea

Sales in Japan & Korea increased by 83% in Danish kroner and by 65% measured in local currencies. In Japan, the GLP-1 market is growing and represents 2.1% of the total diabetes care market compared to 0.8% in 2011. Victoza® is the leader in the Japanese GLP-1 class with a market share of 82%.

NovoNorm®/Prandin®/PrandiMet® (oral antidiabetic products)

Sales of oral antidiabetic products were stable in Danish kroner at DKK 1,369 million, but decreased by 6% measured in local currencies. The sales development reflects modest sales growth in all regions except Europe where generic competition is negatively impacting overall sales in several markets.

Biopharmaceuticals sales development

Sales of biopharmaceutical products increased by 6% measured in Danish kroner to DKK 8,342 million and by 1% measured in local currencies primarily driven by higher sales in the US partly countered by lower sales in Europe.

NovoSeven® (bleeding disorders therapy)

Sales of NovoSeven® increased by 5% in Danish kroner to DKK 4,360 million and were unchanged in local currencies. The market for NovoSeven® remains negatively impacted by stricter budgetary controls and an increased number of inhibitor patients participating in clinical trials. In local currencies, the sales development reflects a rebound in the second quarter of 2012, following the modest sales in the first quarter of 2012. The sales rebound in the second quarter of 2012 is primarily driven by a number of patients with major bleeding episodes in the US which is partly countered by a negative impact from timing of tenders in International Operations.

Norditropin® (growth hormone therapy)

Sales of Norditropin® increased by 15% measured in Danish kroner to DKK 2,786 million and by 9% measured in local currencies. The sales growth is primarily driven by International Operations, partially due to timing of sales, and North America. Novo Nordisk is the second-largest company in the global growth hormone market with a 24% market share measured by volume.

Other products

Sales of other products within biopharmaceuticals, which predominantly consist of hormone replacement therapy (HRT)-related products, decreased by 3% in Danish kroner to DKK 1,196 million and by 8% measured in local currencies. This development primarily reflects an impact from generic competition to Activella® being partly countered by continued sales progress for Vagifem® in the US and a decline in glucagon demand for diagnostic purposes in Japan.

Development in costs

The cost of goods sold grew 10% to DKK 6,827 million, resulting in a gross margin of 81.7% compared to 80.4% in 2011. This improvement primarily reflects an underlying improvement driven by favourable price development in North America and a positive impact from product mix due to increased sales of modern insulins and Victoza®. The gross margin was positively impacted from currencies by around 0.5 percentage point as a result of the appreciation of primarily the US dollar and the Japanese yen versus the Danish krone compared to 2011.

Company Announcement No 50 / 2012
 Financial report for the period 1 January 2012 to 30 June 2012

Page 6 of 24

| | | | | |
|-------------------------|---------------|---------------|-----------------|-------------|
| Novo Nordisk A/S | Novo Allé | Telephone: | Internet: | CVR number: |
| Investor Relations | 2880 Bagsværd | +45 4444 8888 | novonordisk.com | 24256790 |
| | Denmark | Telefax: | | |
| | | +45 4444 6626 | | |

Total non-production-related costs increased by 11% to DKK 16,678 million and by 7% in local currencies.

Sales and distribution costs increased by 13% to DKK 10,053 million and by 8% in local currencies. The cost increase in local currencies is driven by increased marketing costs in the US, sales and marketing investments in selected countries in International Operations as well as the sales force expansion of approximately 300 sales representatives in China in mid-2011.

Research and development costs increased by 10% to DKK 5,070 million and by 8% in local currencies. The cost increase in local currencies is primarily driven by development costs related to the on-going phase 3 trials for liraglutide in obesity and the phase 3a trials for IDegLira, a fixed ratio combination of insulin degludec and liraglutide. Within biopharmaceuticals, costs are primarily related to the continued progress of the portfolio of development projects within haemophilia and the phase 2 trial for anti-IL-20, a recombinant human monoclonal antibody, in rheumatoid arthritis.

Licence fees and other operating income constituted DKK 324 million compared to DKK 245 million in 2011. This development reflects a higher level of recurring royalty income.

Net financials

Net financials showed a net expense of DKK 1,038 million compared to a net expense of DKK 25 million in 2011.

In line with Novo Nordisk's treasury policy the most significant foreign exchange risks for the group have been hedged primarily through forward currency contracts. Reflecting the portfolio of foreign currency exchange hedging contracts the foreign exchange result was an expense of DKK 963 million compared to an income of DKK 32 million in 2011. This development reflects losses on foreign exchange hedging involving especially the US dollar and the Japanese yen due to their appreciation versus Danish kroner compared to the exchange rate level prevailing in 2011.

Key developments in the second quarter

Please refer to appendix 1 for an overview of the quarterly numbers in DKK.

Sales in the second quarter of 2012 increased by 22% to DKK 19,468 million and by 13% in local currencies compared to the same period in 2011. The growth was driven by all three modern insulins and Victoza[®], but Norditropin[®] and NovoSeven[®] also contributed to growth. From a geographic perspective North America and International Operations represented the majority of growth. Victoza[®] sales of DKK 2,293 million in the second quarter of 2012 were primarily driven by the US and Europe.

The gross margin increased to 82.4% in the second quarter of 2012 compared to 80.6% in the same period last year. The underlying increase was driven by a positive impact from pricing in the US and a favourable product mix development. The reported gross margin was further improved by a positive currency impact of 0.8 percentage point.

In the second quarter of 2012, total non-production-related costs increased by 10% to DKK 8,545 million and by 5% in local currencies compared to the same period last year.

Company Announcement No 50 / 2012

Page 7 of 24

Financial report for the period 1 January 2012 to 30 June 2012

Novo Nordisk A/S Novo Allé
2880 Bagsværd

Telephone:
+45 4444 8888

Internet:
novonordisk.com

CVR number:
24256790

Investor Relations Denmark

Telefax:
+45 4444 6626

Sales and distribution costs in Danish kroner increased by 12% as reported and by 5% in local currencies in the second quarter of 2012 compared to the same period last year. In local currencies, the cost increase is driven by increased marketing costs in the US, sales and marketing investments in selected countries in International Operations as well as the sales force expansion of approximately 300 sales representatives in China in mid-2011.

Research and development costs in Danish kroner increased by 10% as reported and by 7% in local currencies in the second quarter of 2012 compared to the same period last year. In local currencies, the increased costs primarily reflect the continued progress of key development projects and investments in the expansion of Novo Nordisk's global research activities. The development costs in 2011 included non-recurring impairment charges related to tangible and intangible assets.

Administration costs in Danish kroner were unchanged as reported and declined by 3% in local currencies in the second quarter of 2012 compared to the same period last year. In local currencies, the decline primarily reflects a refund of a previously expensed fine related to an import licence for a major market in International Operations.

Reported operating profit increased by 45% in the second quarter of 2012 compared to the same period last year, and by approximately 30% in local currencies. This primarily reflects the strong sales growth, the improvement in gross margin as well as modest growth levels for both sales and distribution costs and research and development costs relative to sales.

Outlook 2012

The current expectations for 2012 are summarised in the table below:

| Expectations are <i>as reported</i> , if not otherwise stated | Current expectations 9 August 2012 | Previous expectations 27 April 2012 |
|---|--|--|
| Sales growth | | |
| - in local currencies | 9-12% | 8-11% |
| - as reported | Around 7 percentage points higher | Around 4 percentage points higher |
| Operating profit growth | | |
| - in local currencies | Around 15% | At least 10% |
| - as reported | Around 12 percentage points higher | Around 6.5 percentage points higher |
| Net financials | Expense of around DKK 1,950 million | Expense of around DKK 800 million |
| Effective tax rate | Around 23% | Around 23% |
| Capital expenditure | Around DKK 3.5 billion | Around DKK 3.5 billion |
| Depreciation, amortisation and impairment losses | Around DKK 2.9 billion | Around DKK 2.9 billion |
| Free cash flow | Around DKK 19 billion | Around DKK 18 billion |

Novo Nordisk now expects **sales growth** in 2012 of 9-12% measured in local currencies. This is based on expectations of continued market penetration of Novo Nordisk's key products, as well as expectations for continued intense competition, generic competition to oral antidiabetic products and impact from the implementation of healthcare reforms primarily in the US, Europe and China. Given the current level of exchange rates versus Danish kroner, the reported sales growth is now expected to be around 7 percentage points higher than the growth measured in local currencies.

Edgar Filing: NOVO NORDISK A S - Form 6-K

Company Announcement No 50 / 2012

Page 8 of 24

Financial report for the period 1 January 2012 to 30 June 2012

Novo Nordisk A/S Novo Allé
2880 Bagsværd

Telephone:
+45 4444 8888

Internet:
novonordisk.com

CVR number:
24256790

Investor Relations Denmark

Telefax:
+45 4444 6626

For 2012, **operating profit growth** is now expected to be around 15% measured in local currencies. This reflects a significant increase in costs in the second half of 2012 driven by the expansion of the US sales force, launch preparations for Tresiba®, as well as sales and marketing investments in China and a selected number of countries in International Operations. The expectation for a higher level of operating profit growth reflects the increased expectations for sales growth and a deferral of significant costs related to the US launch of Tresiba® to 2013, which previously were expected to be incurred in 2012. Given the current level of exchange rates versus Danish kroner, the reported operating profit growth is now expected to be around 12 percentage points higher than growth measured in local currencies.

For 2012, Novo Nordisk now expects a **net financial expense** of around DKK 1,950 million. The current expectation primarily reflects losses associated with currency hedging contracts following the appreciation of the US dollar and the Japanese yen versus Danish kroner compared to the exchange rates prevailing in 2011. The expectations for losses related to currency hedging contracts are more than offset by the expected significant positive net impact on reported operating profit from the appreciation of invoicing currencies versus Danish kroner.

Foreign exchange hedging losses of approximately DKK 500 million, as of 7 August, are deferred for future income recognition in 2013 when the hedged operating cash flows will be realised.

The **effective tax rate** for 2012 is still expected to be around 23%.

Capital expenditure is still expected to be around DKK 3.5 billion in 2012, primarily related to investments in filling capacity and a prefilled device production facility in Denmark. Expectations for **depreciation, amortisation and impairment losses** are still expected to be around DKK 2.9 billion, and **free cash flow** is now expected to be around DKK 19 billion reflecting the increased expectations for operating profit growth.

All of the above expectations are based on the assumption that the global economic environment will not significantly change business conditions for Novo Nordisk during the remainder of 2012 and that currency exchange rates, especially the US dollar, will remain at the current level versus the Danish krone. Please refer to appendix 7 for key currency assumptions.

Novo Nordisk has hedged expected net cash flows in a number of invoicing currencies and, all other things being equal, movements in key invoicing currencies will impact Novo Nordisk's operating profit as outlined in the table below.

| Key invoicing currencies | Annual impact on Novo Nordisk's operating profit of a 5% movement in currency | Hedging period (months) |
|--------------------------|---|-------------------------|
| USD | DKK 825 million | 11 |
| JPY | DKK 200 million | 12 |
| CNY | DKK 110 million | 12* |
| GBP | DKK 80 million | 11 |

* USD used as proxy when hedging Novo Nordisk's CNY currency exposure

The financial impact from foreign exchange hedging is included in Net financials.

Company Announcement No 50 / 2012

Page 9 of 24

Financial report for the period 1 January 2012 to 30 June 2012

| | | | | |
|-------------------------|---------------|---------------|-----------------|-------------|
| Novo Nordisk A/S | Novo Allé | Telephone: | Internet: | CVR number: |
| Investor Relations | 2880 Bagsværd | +45 4444 8888 | novonordisk.com | 24256790 |
| | Denmark | Telefax: | | |
| | | +45 4444 6626 | | |

Research and development update

Diabetes care: Insulin and GLP-1

Tresiba® and Ryzodeg® regulatory update

The regulatory reviews for Tresiba® (the intended brand name for insulin degludec) and Ryzodeg® (the intended brand name for insulin degludec/insulin aspart) continue to progress. Novo Nordisk has now submitted Tresiba® and Ryzodeg® for regulatory review in the US, EU, Japan, Switzerland, Canada, South Africa, India, Australia, Brazil, Mexico and Russia. In July, Novo Nordisk announced that the US Food and Drug Administration (FDA) has informed the company that an FDA Advisory Committee meeting is tentatively scheduled for 8 November 2012 to discuss the submitted New Drug Applications (NDA) for Tresiba® and Ryzodeg®. The FDA has not informed Novo Nordisk about a new action date to replace the revised action date, 29 October, announced in June 2012.

American Diabetes Association (ADA) meeting 8-12 June 2012 in Philadelphia, USA

At the annual meeting of the American Diabetes Association (ADA) held in Philadelphia, Novo Nordisk presented results from the company's broad diabetes research and development activities. Novo Nordisk had a solid scientific presence with 60 accepted abstracts including four orals and four late-breaking abstracts. Key presentations by Novo Nordisk focused on Tresiba® and included a pre-specified meta-analysis of the rate of hypoglycaemia across phase 3a trials comparing Tresiba® with insulin glargine. The meta-analysis, for which headline data previously were announced in February 2011, showed that treatment with Tresiba® resulted in significantly lower rates of overall and nocturnal hypoglycaemia. For patients with type 2 diabetes, there was a statistically significant difference for both overall and nocturnal hypoglycaemia, whereas for people with type 1 diabetes, there was a statistically significant difference for nocturnal hypoglycaemia.

First phase 3a clinical trial results for IDegLira (NN9068)

DUAL 1, the first phase 3a trial with IDegLira, a fixed ratio combination of the ultra-long-acting insulin degludec (Tresiba®) and the once daily human GLP-1 analogue, liraglutide (Victoza®), for treatment of patients with type 2 diabetes has been completed. In DUAL 1, more than 1,600 patients with type 2 diabetes, previously inadequately controlled on one or two oral anti-diabetic drugs (OADs), were randomised to 26 weeks of once-daily treatment with either IDegLira, Tresiba® or Victoza®.

After 26 weeks, patients randomised to Tresiba® or Victoza® obtained levels of blood sugar control comparable to earlier findings, while patients randomised to IDegLira experienced a statistically significant greater reduction in HbA_{1c}. The trial thus met its primary endpoints of superiority compared to Victoza® and non-inferiority compared to Tresiba®. Starting from a baseline HbA_{1c} of 8.3%, 81% of patients using IDegLira achieved the ADA and the European Association for the Study of Diabetes (EASD) HbA_{1c} treatment target of 7%, and 70% reached the American Academy of Clinical Endocrinology (AACE) target of 6.5%. The corresponding numbers for Tresiba® and Victoza® were 65% and 61% for the ADA target, and 48% and 41% for the AACE target, respectively.

The low rate of hypoglycaemia observed in patients treated with Tresiba® was comparable to that observed in the recently finalised phase 3 programme. The greater HbA_{1c} reduction in patients treated with IDegLira, resulting from the combined effect of the ultra-long-acting insulin Tresiba® and the once daily GLP-1 analogue Victoza®, was associated with a statistically significant lower rate of confirmed hypoglycaemia compared to treatment with Tresiba® alone.

Company Announcement No 50 / 2012

Page 10 of 24

Financial report for the period 1 January 2012 to 30 June 2012

| | | | | |
|-------------------------|---------------|---------------|-----------------|-------------|
| Novo Nordisk A/S | Novo Allé | Telephone: | Internet: | CVR number: |
| | 2880 Bagsværd | +45 4444 8888 | novonordisk.com | 24256790 |
| Investor Relations | Denmark | Telefax: | | |
| | | +45 4444 6626 | | |

The patients treated with Victoza[®] experienced a weight loss of 3 kg while the patients treated with Tresiba[®] saw a weight increase of around 1.5 kg. Patients treated with IDegLira experienced a weight loss around 0.5 kg.

Tresiba[®] and Victoza[®] both confirmed previous safety and tolerability profiles and no apparent differences between the three treatment groups were observed with respect to adverse events and standard safety parameters.

Overall, the data from DUAL I reconfirm the competitive profiles of Tresiba[®] and Victoza[®], and the trial documents that patients can benefit from the advantages of both compounds when combined in one product. Novo Nordisk expects DUAL II, the second phase 3a trial, to be completed towards the end of 2012.

Semaglutide (NN9535) to enter phase 3 as Novo Nordisk's once-weekly GLP-1 candidate

In June, Novo Nordisk announced the decision to initiate the global phase 3 development programme, SUSTAIN , for semaglutide with the first study expected to start in the first half of 2013. Semaglutide successfully completed phase 2 development in 2010. At that time, it was decided to evaluate semaglutide and a once-weekly formulation of liraglutide, being studied in a phase 1 trial, before selecting a candidate for phase 3 development. Upon completion, the phase 1 trial reconfirmed the safety profile of liraglutide, but semaglutide has been assessed to have a more attractive profile for once-weekly administration. In phase 3a, semaglutide will be investigated in more than 8,000 people with diabetes.

Phase 1 trial initiated for OI362GT (NN1954), a new oral insulin

Novo Nordisk has initiated the first phase 1 trial to explore the safety, tolerability, pharmacokinetics and pharmacodynamics of OI362GT in approximately 100 healthy subjects. Trial completion is expected in the first half of 2013.

FDA approves paediatric indication for Levemir[®]

In May, the FDA approved Levemir[®] for use in children aged 2-5. With this label extension, which already is approved in the EU, Levemir[®] is now the modern long-acting insulin offering treatment to the widest range of patients in both regions.

NovoMet[®] approved in China

NovoMet[®] has been approved by the Chinese State Food and Drug Administration (SFDA). NovoMet[®] is a fixed combination of metformin and repaglinide, a compound in the meglitinide class. The product is marketed as PrandiMet[®] in the US. The tablet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus who are already treated with both a meglitinide and metformin or who have inadequate glycaemic control on either a meglitinide or metformin alone. Launch is expected towards the end of 2013.

NovoPen[®] 5, a new durable insulin pen, launched

In June, Novo Nordisk launched NovoPen[®] 5, a novel durable insulin pen for adults, in Denmark. The design of NovoPen[®] 5 is based on the NovoPen[®] 4 platform with the addition of an integrated memory function displaying last dose information. Novo Nordisk expects to launch NovoPen[®] 5 in more European countries in the second half of 2012.

Biopharmaceuticals: Haemophilia

Recombinant factor XIII approved in Canada

In July, the Canadian Health authority, Health Canada, was the first to approve Novo Nordisk's new recombinant factor XIII product. The product was approved for once-monthly prophylactic treatment of congenital FXIII A-subunit deficiency and will be the only recombinant treatment

Company Announcement No 50 / 2012

Financial report for the period 1 January 2012 to 30 June 2012

Novo Nordisk A/S Novo Allé
2880 Bagsværd
Investor Relations Denmark

Telephone: +45 4444 8888
Internet: novonordisk.com
Telefax: +45 4444 6626

CVR number:
24256790

Page 11 of 24

option for this rare disease, affecting approximately 900 people worldwide. Launch is expected in the second half of 2012 under the brand name Tretten®.

In Europe, the adoption by the European Commission of the previously announced positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is now expected in September 2012.

Anti-drug antibodies observed in vatreptacog alfa (NN1731) phase 3 trial

Novo Nordisk recently completed the pivotal phase 3 trial for vatreptacog alfa, a fast-acting recombinant coagulation factor VIIa analogue, in haemophilia patients with inhibitors. In the trial, anti-drug antibodies were observed in a few patients and in one patient, a potentially neutralising effect has now been observed in one sample. The impact of this finding on the project is being evaluated as part of the phase 3 programme completion. Final results of the blinded and randomised trial including 72 patients and 568 treated bleeding episodes are expected in October 2012.

Biopharmaceuticals: Inflammation

Phase 2b trial with Anti-IL-20 (NN8226) initiated in patients with rheumatoid arthritis

Novo Nordisk has initiated the first phase 2b clinical trial with Anti-IL-20, a fully human monoclonal antibody, in patients with active rheumatoid arthritis. The trial will investigate the effects of different doses of Anti-IL-20 compared to placebo, when administered as weekly subcutaneous injections in patients on a stable background of methotrexate therapy who are inadequate responders to anti-TNFa biologics.

Phase 1 trial initiated for Anti-C5aR-215 (NN8210) for rheumatoid arthritis

In June, Novo Nordisk initiated the first phase 1 trial for Anti-C5aR-215, a recombinant human monoclonal antibody. The aim of this trial is to describe the safety and tolerability of single intravenous and subcutaneous doses of Anti-C5aR-215 in patients with active rheumatoid arthritis on a background of methotrexate treatment. The trial will enrol 36 subjects with active rheumatoid arthritis and is expected to be completed by mid-2013.

Sustainability update

The number of full-time employees was 32,819 as of 30 June 2012 compared to 31,549 as of 30 June 2011. The expansion was led by countries in International Operations and within Research and Development in Denmark, India, China and the US.

On the occasion of the United Nations Conference on sustainable development, Rio+20, held in Rio de Janeiro in June 2012 to celebrate and renew the political commitments from the first Earth Summit in 1992, Novo Nordisk marked the company's 20 years of focus on sustainability. The Triple Bottom Line approach, today an integral part of Novo Nordisk's governance, decision-making and performance reporting, builds on the principles of sustainable development launched at the summit in 1992. The company's journey is documented in the book *20 years in the business of sustainability*, which is available on the webpage: www.novonordisk.com/sustainability as a PDF file.

A key element in these efforts is Novo Nordisk's global Changing Diabetes® initiative. In late April 2012, the OECD and the Danish Diabetes Association, with support from Novo Nordisk, hosted the European Diabetes Leadership Forum in Copenhagen. The Forum convened more than 700 policymakers and healthcare leaders with the objective of finding innovative solutions to better manage chronic diseases with diabetes as the focal point, in light of the growing

Company Announcement No 50 / 2012

Page 12 of 24

Financial report for the period 1 January 2012 to 30 June 2012

Novo Nordisk A/S Novo Allé
2880 Bagsværd
Investor Relations Denmark

Telephone: +45 4444 8888
Internet: novonordisk.com
Telefax: +45 4444 6626

CVR number:
24256790

diabetes prevalence and its economic implications. The outcomes of the Forum were collected in the Copenhagen Roadmap which was released in June. The Copenhagen Roadmap presents practical and concrete initiatives to improve diabetes prevention, early detection and intervention as well as management and control.

Equity

Total equity was DKK 31,334 million at the end of the first six months of 2012, equivalent to 51.4% of total assets, compared to 60.1% at the end of the first six months of 2011. The development in equity ratio is primarily driven by the timing of share repurchases and increased dividend payments lowering retained earnings while the liabilities grow in line with operations. Please refer to appendix 5 for further elaboration of changes in equity.

Treasury shares and 2012 share repurchase programme

On 2 May 2012, Novo Nordisk announced the purchase of 5,100,000 B shares for an amount of DKK 4.2 billion from Novo A/S. Also on 2 May 2012, Novo Nordisk announced a DKK 1.8 billion share repurchase programme as part of the overall DKK 12 billion programme to be executed during a 12-month period starting 2 February 2012. The purpose of the programme is to reduce the company's share capital. Under the programme announced 2 May, Novo Nordisk has repurchased B shares for an amount of DKK 1.8 billion in the period from 2 May 2012 to 3 August 2012, when the programme was concluded. Novo Nordisk has now repurchased 10,365,758 shares corresponding to a total value of DKK 8.5 billion under the DKK 12 billion programme.

As per 3 August 2012, Novo Nordisk A/S and its wholly-owned affiliates owned 15,226,277 of its own B shares, corresponding to 2.7% of the total share capital.

As part of the execution of Novo Nordisk A/S DKK 12 billion share repurchase programme for a 12-month period starting 2 February 2012, a new share repurchase programme has now been initiated in accordance with the provisions of the European Commission's regulation No 2273/2003 of 22 December 2003 (The Safe Harbour Regulation). For that purpose, J.P. Morgan Securities Ltd. as lead manager will repurchase shares on behalf of Novo Nordisk for an amount of up to DKK 2.0 billion during the trading period from 9 August 2012 to 29 October 2012. A maximum of 95,044 shares can be bought during one single trading day, equal to 20% of the average daily trading volume of Novo Nordisk B shares on NASDAQ OMX

Copenhagen during the month of July 2012, and a maximum of 5,512,552 shares in total can be bought during the trading period. At least once every seven trading days, Novo Nordisk will issue an announcement in respect of the transactions made under the repurchase programme.

Legal update

In May 2009, Novo Nordisk entered into a Deferred Prosecution Agreement (DPA) for a three-year period with the US Department of Justice relating to certain actions undertaken by Novo Nordisk under the Oil For Food Programme for Iraq. Novo Nordisk had to comply with the terms of the DPA in order for the case to be dismissed. Novo Nordisk has subsequently enacted a detailed programme to ensure compliance with the DPA, including a reinforced governance structure, enhanced third-party due diligence systems and periodic testing of systems, policies and procedures. The DPA expired on 11 May 2012, and the U.S. District Court for the District of Columbia has dismissed the case. Accordingly, the DPA no longer imposes any obligations on Novo Nordisk.

Company Announcement No 50 / 2012

Page 13 of 24

Financial report for the period 1 January 2012 to 30 June 2012

Novo Nordisk A/S Novo Allé
2880 Bagsværd
Investor Relations Denmark

Telephone: +45 4444 8888
Internet: novonordisk.com
Telefax: +45 4444 6626

CVR number:
24256790

As of 6 August 2012, Novo Nordisk Inc., along with a majority of the hormone therapy product manufacturers in the US, is a defendant in product liability lawsuits related to hormone therapy products. These lawsuits currently involve a total of 41 individuals who allege use of a Novo Nordisk hormone therapy product. The products (Activella® and Vagifem®) have been sold and marketed in the US since 2000. Until July 2003, the products were sold and marketed exclusively in the US by Pharmacia & Upjohn Company (now Pfizer Inc.). Furthermore, 54 individuals currently allege, in relation to similar lawsuits against Pfizer Inc., that they have also used a Novo Nordisk hormone therapy product. Pfizer Inc. has publicly announced the settlement of many of its hormone therapy cases. The reduction in pending cases is the result of Pfizer Inc. settling several cases that also involve Novo Nordisk's products. Currently, Novo Nordisk does not have any trials scheduled in 2012. Novo Nordisk does not expect the pending claims to have a material impact on its financial position, operating profit and cash flow.

After the US Supreme Court reversed the decision of the US Court of Appeals for the Federal Circuit (CAFC) on 17 April 2012 and held that Caraco Pharmaceutical Laboratories, Ltd. and its parent Sun Pharmaceutical Industries, Ltd. (collectively Caraco) have the right to file a counterclaim to correct Novo Nordisk's use code for Prandin® contained in the Orange Book, the case was remanded to the CAFC for further proceedings. Caraco had argued that Novo Nordisk's use code for Prandin® was too broad and prevented generics from marketing a generic version of Prandin® (repaglinide). On 30 July 2012, the CAFC ordered Novo Nordisk to file a revised use code with the FDA consistent with the guidance contained in its order. As a result, the appeal related to the use code currently before the CAFC is now concluded. Novo Nordisk's appeal of the decision by the US District Court for the Eastern District of Michigan, which held US Patent No. 6,677,358 covering the use of repaglinide and metformin invalid and unenforceable, will proceed before the CAFC. A decision is expected in 2013.

Financial calendar

| | |
|-----------------|---|
| 3 October 2012 | Novo Nordisk's investor and analyst event at EASD |
| 31 October 2012 | Financial statement for the first nine months of 2012 |
| 31 January 2013 | Financial statement for 2012 |

Conference call details

At 13.00 CET today, corresponding to 7.00 am EDT, a conference call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under Investors Download centre (<http://www.novonordisk.com/investors/download-centre/default.asp>). Presentation material for the conference call will be available approximately one hour prior to the start of the conference call on the same page.

Forward-looking statements

Novo Nordisk's reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document as well as the company's *Annual Report 2011* and Form 20-F, both filed with the SEC in February 2012, and written information released, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain forward-looking statements. Words such as believe, expect, may, will, plan, strategy, prospect, foresee, estimate, project, anticipate, target and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. Examples of such forward-looking statements include, but are not limited to:

Company Announcement No 50 / 2012

Page 14 of 24

Financial report for the period 1 January 2012 to 30 June 2012

Novo Nordisk A/S Novo Allé
2880 Bagsværd
Investor Relations Denmark

Telephone: +45 4444 8888
Internet: novonordisk.com
Telefax: +45 4444 6626

CVR number:
24256790

statements of plans, objectives or goals for future operations, including those related to Novo Nordisk's products, product research, product development, product introductions and product approvals as well as cooperation in relation thereto
statements containing projections of or targets for revenues, income (or loss), earnings per share, capital expenditures, dividends, capital structure or other net financials
statements regarding future economic performance, future actions and outcome of contingencies such as legal proceedings, and
statements of the assumptions underlying or relating to such statements.

In this document, examples of forward-looking statements can be found under the headings Outlook 2012, Research and development update, Equity and Legal update.

These statements are based on current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. Novo Nordisk cautions that a number of important factors, including those described in this document, could cause actual results to differ materially from those contemplated in any forward-looking statements.

Factors that may affect future results include, but are not limited to, global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations, delay or failure of projects related to research and/or development, unplanned loss of patents, interruptions of supplies and production, product recall, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Novo Nordisk's products, introduction of competing products, reliance on information technology, Novo Nordisk's ability to successfully market current and new products, exposure to product liability and legal proceedings and investigations, changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing and marketing, perceived or actual failure to adhere to ethical marketing practices, investments in and divestitures of domestic and foreign companies, unexpected growth in costs and expenses, failure to recruit and retain the right employees and failure to maintain a culture of compliance.

Please also refer to the overview of risk factors in Risk Management on pp 22-24 of the *Annual Report 2011* available on the company's website novonordisk.com.

Unless required by law, Novo Nordisk is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this document, whether as a result of new information, future events or otherwise.

Company Announcement No 50 / 2012

Page 15 of 24

Financial report for the period 1 January 2012 to 30 June 2012

| | | | | |
|-------------------------|---------------|---------------|-----------------|-------------|
| Novo Nordisk A/S | Novo Allé | Telephone: | Internet: | CVR number: |
| | 2880 Bagsværd | +45 4444 8888 | novonordisk.com | 24256790 |
| Investor Relations | Denmark | Telefax: | | |
| | | +45 4444 6626 | | |

Management statement

The Board of Directors and Executive Management have reviewed and approved the financial report of Novo Nordisk A/S for the first six months of 2012. The financial report has not been audited or reviewed by the company's independent auditors.

The consolidated financial statements for the first six months of 2012 have been prepared in accordance with IAS 34 Interim Financial Reporting and on the basis of the same accounting policies as applied in the Annual Report 2011 of Novo Nordisk. Furthermore, the financial report, including the consolidated financial statements for the first six months of 2012 and Management's review, has been prepared in accordance with additional Danish disclosure requirements for interim reports of listed companies.

In our opinion, the accounting policies used are appropriate and the overall presentation of the consolidated financial statements for the first six months of 2012 is adequate. Furthermore, in our opinion, Management's review includes a true and fair account of the development in the operations and financial circumstances, of the results for the period and of the financial position of the Group as well as a description of the most significant risks and elements of uncertainty facing the Group in accordance with Danish disclosure requirements for listed companies.

Bagsværd, 9 August 2012

Executive Management:

Lars Rebien Sørensen Jesper Brandgaard
President and CEO *CFO*

Lise Kingo Kåre Schultz Mads Krogsgaard Thomsen
COS *COO* *CSO*

Board of Directors:

Sten Scheibye Göran Ando Bruno Angelici
Chairman *Vice chairman*

Henrik Gürtler Ulrik Hjulmand-Lassen Thomas Paul Koestler

Anne Marie Kverneland Kurt Anker Nielsen Søren Thuesen Pedersen

Hannu Ryöppönen Stig Strøbæk Liz Hewitt

Company Announcement No 50 / 2012

Financial report for the period 1 January 2012 to 30 June 2012

Novo Nordisk A/S Novo Allé
2880 Bagsværd
Investor Relations Denmark

Telephone: Internet:
+45 4444 8888 novonordisk.com
Telefax:
+45 4444 6626

Internet:
novonordisk.com

Page 16 of 24

CVR number:
24256790

Contacts for further information

Media:

Mike Rulis
Tel: (+45) 4442 3573
mike@novonordisk.com

Investors:

Kasper Roseeuw Poulsen
Tel: (+45) 4442 4303
krop@novonordisk.com

Lars Borup Jacobsen
Tel: (+45) 3075 3479
lbj@novonordisk.com

Frank Daniel Mersebach
Tel: (+45) 4442 0604
fdni@novonordisk.com

In North America:

Ken Inchausti
Tel: (+1) 609 786 8316
kiu@novonordisk.com

In North America

Jannick Lindegaard
Tel: (+1) 609 786 4575
jllis@novonordisk.com

Further information about Novo Nordisk is available on the company's website novonordisk.com

Company Announcement No 50 / 2012

Financial report for the period 1 January 2012 to 30 June 2012

Novo Nordisk A/S Novo Allé
2880 Bagsværd
Investor Relations Denmark

Telephone:
+45 4444 8888
Telefax:
+45 4444 6626

Internet:
novonordisk.com

CVR number:
24256790

Page 17 of 24

Appendix 1: Quarterly numbers in DKK

(Amounts in DKK million, except number of employees, earnings per share and number of shares outstanding).

| | 2012 | | 2011 | | | | % change Q2 2012 vs Q2 2011 |
|--|---------------|---------------|---------------|---------------|---------------|---------------|--------------------------------------|
| | Q2 | Q1 | Q4 | Q3 | Q2 | Q1 | |
| Sales | 19,468 | 17,751 | 18,120 | 16,532 | 16,001 | 15,693 | 22% |
| Gross profit | 16,044 | 14,348 | 14,998 | 13,281 | 12,902 | 12,576 | 24% |
| <i>Gross margin</i> | <i>82.4%</i> | <i>80.8%</i> | <i>82.8%</i> | <i>80.3%</i> | <i>80.6%</i> | <i>80.1%</i> | |
| Sales and distribution costs | 5,203 | 4,850 | 5,387 | 4,724 | 4,633 | 4,260 | 12% |
| <i>Percentage of sales</i> | <i>26.7%</i> | <i>27.3%</i> | <i>29.7%</i> | <i>28.6%</i> | <i>29.0%</i> | <i>27.1%</i> | |
| Research and development costs | 2,563 | 2,507 | 2,752 | 2,263 | 2,323 | 2,290 | 10% |
| <i>Percentage of sales</i> | <i>13.2%</i> | <i>14.1%</i> | <i>15.2%</i> | <i>13.7%</i> | <i>14.5%</i> | <i>14.6%</i> | |
| Administrative expenses | 779 | 776 | 923 | 788 | 778 | 756 | 0% |
| <i>Percentage of sales</i> | <i>4.0%</i> | <i>4.4%</i> | <i>5.1%</i> | <i>4.8%</i> | <i>4.9%</i> | <i>4.8%</i> | |
| Licence fees and other operating income (net) | 154 | 170 | 145 | 104 | 97 | 148 | 59% |
| Operating profit | 7,653 | 6,385 | 6,081 | 5,610 | 5,265 | 5,418 | 45% |
| <i>Operating margin</i> | <i>39.3%</i> | <i>36.0%</i> | <i>33.6%</i> | <i>33.9%</i> | <i>32.9%</i> | <i>34.5%</i> | |
| Share of profit/(loss) in associated companies | - | - | (4) | - | - | - | N/A |
| Financial income | 146 | 47 | 6 | 154 | 270 | 84 | (46%) |
| Financial expenses | 856 | 375 | 272 | 308 | 167 | 212 | 413% |
| Net financials | (710) | (328) | (270) | (154) | 103 | (128) | (789%) |
| Profit before income taxes | 6,943 | 6,057 | 5,811 | 5,456 | 5,368 | 5,290 | 29% |
| Net profit | 5,346 | 4,664 | 4,689 | 4,201 | 4,134 | 4,073 | 29% |
| Depreciation, amortisation and impairment losses | 656 | 638 | 692 | 615 | 825 | 605 | (20%) |
| Capital expenditure | 855 | 516 | 1,182 | 645 | 627 | 549 | 36% |
| Net cash generated from operating activities | 5,823 | 6,915 | 3,981 | 7,754 | 4,531 | 5,108 | 29% |
| Free cash flow | 4,945 | 6,366 | 2,751 | 7,066 | 3,792 | 4,503 | 30% |
| Total assets | 60,978 | 61,210 | 64,698 | 62,013 | 61,528 | 59,001 | (1%) |
| Total equity | 31,334 | 32,358 | 37,448 | 35,428 | 36,966 | 34,768 | (15%) |
| <i>Equity ratio</i> | <i>51.4%</i> | <i>52.9%</i> | <i>57.9%</i> | <i>57.1%</i> | <i>60.1%</i> | <i>58.9%</i> | |
| Full-time employees at the end of the period | 32,819 | 32,252 | 32,136 | 32,016 | 31,549 | 30,867 | 4% |
| Basic earnings per share/ADR (in DKK) | 9.72 | 8.38 | 8.40 | 7.45 | 7.26 | 7.13 | 34% |
| Diluted earnings per share/ADR (in DKK) | 9.67 | 8.32 | 8.33 | 7.39 | 7.21 | 7.06 | 34% |
| Average number of shares outstanding (million) | 549.1 | 556.7 | 557.6 | 563.5 | 569.1 | 571.6 | (4%) |

Edgar Filing: NOVO NORDISK A S - Form 6-K

| | | | | | | | |
|---|---------------|---------------|---------------|---------------|---------------|---------------|------------|
| Average number of shares outstanding incl dilutive effect of options 'in the money' (million) | 552.4 | 560.5 | 561.9 | 568.1 | 573.8 | 576.7 | (4%) |
| Sales by business segment: | | | | | | | |
| Modern insulins (insulin analogues) | 8,613 | 7,867 | 7,856 | 7,232 | 6,972 | 6,705 | 24% |
| Human insulins | 2,781 | 2,718 | 2,790 | 2,698 | 2,642 | 2,655 | 5% |
| Protein-related products | 621 | 625 | 569 | 574 | 527 | 639 | 18% |
| Victoza® | 2,293 | 1,990 | 2,096 | 1,547 | 1,250 | 1,098 | 83% |
| Oral antidiabetic products (OAD) | 653 | 716 | 649 | 562 | 653 | 711 | 0% |
| Diabetes care total | 14,961 | 13,916 | 13,960 | 12,613 | 12,044 | 11,808 | 24% |
| NovoSeven® | 2,451 | 1,909 | 2,131 | 2,044 | 2,140 | 2,032 | 15% |
| Norditropin® | 1,440 | 1,346 | 1,340 | 1,275 | | | |